 |
|
Researchers report the cloning of a key group of human genes, the protein kinases
May 05, 2008Although the human genome has been sequenced, research into mechanism of action of genes has been hampered by the fact that most human genes have not been isolated. This is true for even the most common class of cancer-associated genes, the protein kinases, which mediate the majority of signaling events in cells by phosphorylating and modulating the activity of other proteins. It has been estimated by systematic gene sequencing efforts that up to a quarter of kinases may play a role in human cancers.
In a study published in the 2nd of May issue of Cell, a research teams led by Professor Jussi Taipale from the National Public Health Institute and University of Helsinki, Finland, Professor Olli Kallioniemi from Institute for Molecular Medicine Finland (FIMM), and Dr. Wei-Wu He from the US-based biotechnology company Origene Technologies, Inc., report cloning of nearly all predicted human protein kinase genes in functional form, and generation of a corresponding set of kinases lacking catalytic activity that are necessary for functional studies. They further used the kinome collection in several high-throughput screens, including a screen which identified two novel kinases regulating the Hedgehog signaling pathway - a key pathway linked to multiple types of human cancer. In addition, together with the group of Dr. Päivi Ojala, University of Helsinki, they identified a novel kinase required for activation of Kaposi's sarcoma herpesvirus.
"The isolated kinase genes form a resource that scientist can now use to systematically map kinase signaling networks in different cellular disease models. The kinases are also promising targets for therapeutic intervention in the treatment of various cancers", Professor Taipale states.
University of Helsinki
University of Helsinki
Protein Kinases Current Events and Protein Kinases News RSSCanadian research breakthrough holds promise for development of effective cancer therapies
Researchers Dr. Marc Therrien at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Dr. Frank Sicheri, at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, have discovered a new target that may be instrumental in the development of new, more effective cancer therapies.
Mutant genes in high-risk childhood leukemias identified
A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death.
Researchers identify key proteins needed for ovulation
Researchers from the National Institutes of Health and other institutions have identified in mice two proteins essential for ovulation to take place.
E. coli persists against antibiotics through HipA-induced dormancy
Bacteria hunker down and survive antibiotic attack when a protein flips a chemical switch that throws them into a dormant state until treatment abates, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan.16 edition of Science.
A new relationship between brain derived neurotrophic factor and inflammatory signaling
In the October 14th edition of Science Signaling researchers at Boston University School of Medicine (BUSM), The Children's Hospital of Philadelphia/University of Pennsylvania School of Medicine and The University of Colorado Denver School of Medicine have shown that the development of epilepsy in adult rats is linked to functional changes in the expression of alpha 1 containing GABA-A receptors, the main inhibitory neurotransmitter receptor in the brain, that may be dependent upon BDNF-induced activation of the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway.
Novel enzyme inhibitor paves way for new cancer drug
Combining natural organic atoms with metal complexes, scientists at The Wistar Institute have developed a new type of enzyme inhibitor capable of blocking a biochemical pathway that plays a key role in cancer development.
Early Phase II results show bosutinib safe, effective for CML
A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting of the American Society of Hematology.
Gene may hold key to future cancer hope
Scientists may have discovered a new way of killing tumours in what they hope could one day lead to alternative forms of cancer treatments.
UCSD study reveals the regulatory mechanism of key enzyme
Research conducted at the University of California, San Diego (UCSD) School of Medicine has shed new light on the structure and function of one of the key proteins in all mammalian cells, protein kinase A (PKA), an enzyme which plays an essential role in memory formation, communication between nerve cells, and cardiac function.
Minimum information standards -- all for 1 and 1 for all
Three papers published by EMBL scientists and their collaborators will make it much easier to share and compare information from large-scale proteomics data. The papers are published in Nature Biotechnology on 8th and 26th August.
More Protein Kinases Current Events and Protein Kinases News Articles
 |
Kinase Inhibitor Drugs (Wiley Series in Drug Discovery and Development) by Rongshi Li (Author), Jeffrey A. Stafford (Author) A comprehensive resource on case studies of marketed kinase drugs and promising drug trials Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inhibitors are in clinical development. In one comprehensive volume, the editors, Dr. Rongshi Li and Dr. Jeffrey Stafford, present timely and important case studies of marketed... |
 |
Jarrow - Creatine Monoydrate, 600 gm 600 gms by Jarrow Formulas Creatine is synthesized in the liver from the amino acidsarginine and glycine and stored in the major muscles, including cardiac and skeletal tissues. Once inside the muscle, creatine is phosphorylated to form creatine phosphate (CP), a high energy substrate that assists in the contraction of the myofibrils (muscle fibers). Creatine Phosphate is utilized to maintain higher levels of ATP (energy molecules) during exercise. Creatine Phosphate maximizes physical performance and reduces exercise fatigue by absorbing hydrogen ions released by muscles in the form of lactic acid. Intense anaerobic exercise, such as weight lifting and sprinting, depletes ATP and greatly increases the demand for creatine. |
 |
Protein Kinase Protocols (Methods in Molecular Biology) by Alastair D. Reith (Editor) GlaxoSmithKline, Essex, UK. Presents a range of techniques and tools for understanding the roles of specific protein kinases within signalling cascades and for identification and evaluation of novel therapeutic targets. For researchers. |
 |
Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development) by Doriano Fabbro (Editor), Frank McCormick (Editor) Leading researchers, from the Novartis group that pioneered Gleevec/Glivec™ and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for... |
 |
Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: Drug Discovery and Development (Wiley Series in Drug Discovery and Development) by Ana Martinez (Editor), Ana Castro (Editor), Miguel Medina (Editor), Binghe Wang (Editor) Many researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It’s a great reference for researchers in drug design and development. |
 |
Mitochondrial Function, Part B, Volume 457: Mitochondrial Protein Kinases, Protein Phosphatases and Mitochondrial Diseases (Methods in Enzymology) by William S. Allison (Editor), Anne Murphy (Editor) The second of two new volumes covering mitochondria, this volume presents methods that have been developed to assess the number and function of nuclear-encoded proteins in the mitochndrion. These diverse chapters focus on regulation of mitochondrial function and mitochondrial diseases, including a section emphasizing the mitochondrial defects associated with type-2 diabetes. The critically acclaimed laboratory standard for 40 years, Methods in Enzymology is one of the most highly respected publications in the field of biochemistry. Since 1955, each volume has been eagerly awaited, frequently consulted, and praised by researchers and reviewers alike. With more than 400 volumes published, each Methods in Enzymology volume presents material that is relevant in today's labs -- truly an... |
 |
The Protein Kinase Factsbook, Two-Volume Set, Volume 1-2: Protein-Tyrosine Kinases by Grahame Hardie (Author), Steven Hanks (Author) How do you keep track of basic information on the proteins you work with? Where do you find details of their physicochemical properties, amino acid sequences, gene organization? Are you tired of scanning review articles, primary papers and databases to locate that elusive fact? The Academic Press FactsBook series will satisfy scientists and clinical researchers suffering from information overload. Each volume provides a catalogue of the essential properties of families of molecules. Gene organization, amino acid sequences, physicochemical properties, and biological activity are presented using a common, easy to follow format. Taken together they compile everything you wanted to know about proteins but were too busy to look for. The Protein Kinase FactsBook: Protein - Tyrosine... |
 |
Protein Kinase Inhibitors, Volume 480 by Kevan Shokat (Editor) |
 |
Protein Kinase C Protocols (Methods in Molecular Biology) by Alexandra C. Newton (Editor) Univ. of California at San Diego, La Jolla. Features readily reproducible techniques for studying the biology of protein kinase C, methods such as translocation and activity assays, instructions and tips to ensure results, and emerging methods such as chemical genetics. For researchers. Hardcover, softcover not available. |
 |
Protein Kinase C (Molecular Biology Intelligence Unit) by Lodewijk V. Dekker (Editor) Protein Kinase C is a pivotal component of the mechanism that allows a cell to respond to its changing environment. In this book, the most significant advances in recent basic research on Protein Kinase C are explained by active researchers in the field. The first seven chapters provide a comprehensive account of the fundamental structural and biochemical properties of Protein Kinase C. The remaining chapters contain overviews of the function of Protein Kinase C, both in lower organisms and in mammalian cells, the latter with a focus on immune cells and nerve cells. This book is the only recent publication devoted entirely to Protein Kinase C and forms a major point of reference for those active in the field. In addition it will appeal to those with a general interest in biochemistry,... |
| © 2009 BrightSurf.com |